Protalix BioTherapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	14.68	19.76	23.63	17.11	38.99
Short-Term Investments	15.59	15.07	20.93	5.07	-
Cash & Short-Term Investments	30.27	34.83	44.56	22.18	38.99
Cash Growth	-13.08%	-21.84%	100.90%	-43.11%	1.14%
Accounts Receivable	8.84	2.91	5.27	4.59	3.44
Inventory	25.73	21.24	19.05	16.8	17.95
Other Current Assets	1.83	1.1	1.06	1.31	1.29
Total Current Assets	66.67	60.08	69.93	44.88	61.67
Net Property, Plant & Equipment	12.58	10.02	10.88	9.64	9.92
Other Long-Term Assets	3.09	3.32	3.62	1.27	2.08
Total Assets	82.35	73.42	84.43	55.79	73.67
Accounts Payable	5.26	4.53	4.32	5.86	6.99
Accrued Expenses	19.88	19.59	19.55	12.27	16.43
Current Portion of Long-Term Debt	-	-	20.25	-	-
Current Portion of Leases	1.38	1.5	1.41	1.12	1.21
Unearned Revenue	-	-	-	13.18	8.55
Total Current Liabilities	26.52	25.62	45.53	32.43	33.18
Long-Term Debt	-	-	-	28.19	27.89
Long-Term Leases	6.94	4.03	4.62	4.17	4.38
Other Long-Term Liabilities	0.66	0.56	0.71	1.64	14.26
Total Long-Term Liabilities	7.6	4.59	5.34	34	46.53
Total Liabilities	34.12	30.21	50.87	66.43	79.7
Common Stock	0.08	0.08	0.07	0.05	0.05
Additional Paid-in Capital	433.15	421.53	415.05	379.17	368.85
Retained Earnings	-385	-378.39	-381.55	-389.86	-374.93
Shareholders' Equity	48.23	43.21	33.57	-10.64	-6.04
Total Liabilities & Equity	82.35	73.42	84.43	55.79	73.67
Total Debt	8.32	5.53	26.28	33.47	33.47
Net Cash (Debt)	21.95	29.3	18.28	-11.29	5.52
Net Cash Growth	-25.09%	60.31%	-	-	-
Net Cash Per Share	0.28	0.36	0.22	-0.23	0.13
Book Value	48.23	43.21	33.57	-10.64	-6.04
Book Value Per Share	0.61	0.53	0.41	-0.22	-0.14
Tangible Book Value	48.23	43.21	33.57	-10.64	-6.04
Tangible Book Value Per Share	0.61	0.53	0.41	-0.22	-0.14

Updated Mar 18, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q